C-Reactive Protein Testing Market by Assay Type (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assay, and Others) and Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory

C-Reactive Protein Testing Market by Assay Type (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assay, and Others) and Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

The global c-reactive protein testing market was valued at $2,765.07 million in 2020, and is estimated to reach $3,568.69 million by 2030, growing at a CAGR of 2.4% from 2021 to 2030. C-reactive protein (CRP) is a ring shaped pentameric protein present in the blood plasma whose levels rise in reaction to inflammation. It is produced by the liver and is a hepatic acute phase protein that rises in response to macrophages and T cells secreting interleukin. Inflammation is the body's way of protecting tissues after an injury or infection. It can also be caused by autoimmune disorders and various chronic diseases such as cardiovascular diseases, diabetes, and rheumatoid arthritis. CRP test measures the level of CRP in the blood caused in reaction to an inflammation.

CRP has anti-inflammatory as well as pro-inflammatory properties. It facilitates in recognition and removal of foreign pathogens and damaged cells. CRP levels of less than 0.3 mg/L are considered normal and are found in majority of healthy adults. Normal or minor elevation is defined as 0.3 to 1.0 mg/L and can be seen in obesity, pregnancy, depression, diabetes, common cold, sedentary lifestyle, and cigarette smoking. 1.0 to 10.0 mg/L is a moderate elevation caused primarily by systemic inflammation or other autoimmune diseases, malignancies, myocardial infarction, pancreatitis, and bronchitis. A level of more than 10.0 mg/L, indicating a significant elevation, is caused primarily by acute bacterial infections, viral infections, systemic vasculitis, and major trauma. A level of more than 50.0 mg/L indicates a severe elevation caused by acute bacterial infections.

Factors that drive growth of the market include increase in prevalence of inflammatory disorders and rise in cardiovascular diseases, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated 17.9 million people dying from CVDs in 2019, accounting for 32% of all global deaths. 85% of these deaths were caused by a heart attack or a stroke. In addition, according to the Center for Disease Control and Prevention, coronary heart disease is the most common type of heart disease, killing 360,900 people in 2019, and around 18.2 million adults aged 20 or older have CAD in the U.S. Thus, such significantly high rates of cardiac diseases boost the CRP testing market as CRP levels can indicate how vulnerable an individual is for developing cardiovascular problems. However, wide range of availability and advancement in other testing methods for cardiac diseases such as electrocardiogram (ECG) exercise stress test, echocardiogram (ultrasound), magnetic resonance imaging (MRI), coronary computed tomography angiogram (CCTA) and their rapid, accurate results is expected to restrain the market growth.

Other factors that propel the market growth include increase in unhealthy lifestyle among population; growth in chronic disorders, early diagnosis of medical conditions; and various initiatives taken by governments, non-profit organizations, and key players to increase the testing of CRP to detect various anomalies such as estimation of having a stroke or cardiac arrests in future, lupus, or other diseases by spreading awareness regarding the same.

Furthermore, technological advancements in diagnostics, adoption of point of care devices, collaborations, and product approvals further boost the market growth. For instance, in January 2022, LumiraDx announced that it received CE mark approval for its LumiraDx C-reactive protein test. It is a small and portable microfluidic immunoassay test used for quantitative determination of C-reactive protein, delivering results within four minutes. Thus, such approvals further boost availability and number of CRP testings and propels the market.

However, lack of public awareness and availability of alternative disease testing methods are expected to impede growth of the market. Furthermore, increase in applications for test, point of care testing, large target populations, higher global health care awareness, presence of a plethora of products in the pipeline, and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

The global C-reactive protein testing market is segmented on the basis of assay type, application, and region. On the basis of assay type, the market is categorized into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. By application, it is divided into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Horiba, Ltd., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Merck KGAA (Millipore Sigma), Randox Laboratories Limited, Thermo Fisher Scientific, Inc., and Zoetis Inc. (Abaxis Inc.).

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.
This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS


By Assay Type

Enzyme-linked immunosorbent assay (ELISA)
Chemiluminescence immunoassay (CLIA)
Immunoturbidimetric assays
Others

By Application

Diabetes
Rheumatoid Arthritis
Cardiovascular Disease
Inflammatory Bowel Disease
Others

By Region

North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

KEY MARKET PLAYERS

Abbott Laboratories
Danaher Corporation (Beckman Coulter Inc.)
F. Hoffmann-La Roche AG
Horiba, Ltd.
Quest Diagnostics Incorporated
Merck KGAA (Millipore Sigma)
Randox Laboratories Limited
Laboratory Corporation of America Holdings
Thermo Fisher Scientific, Inc.
Zoetis Inc. (Abaxis Inc.)